Our take on Avidity's FORTITUDE phase 1/2 trial data

MyFSHD
11/06/2025 54 min Temporada 4 Episodio 8

Listen "Our take on Avidity's FORTITUDE phase 1/2 trial data"

Descargar episodio Ver en sitio original

Episode Synopsis

"I'll have what she's having." We'll take you through and discuss the recent release of Avidity Biosciences topline results from the phase 1/2 FORTITUDE trial and the preliminary data from the biomarker cohort extension.

More episodes of the podcast MyFSHD

All-in-one version of our evaluation of EPI-321 data and trial 14/09/2025
Our evaluation and opinions of the EPI-321 clinical trial design and potential based on the pre-clinical data 06/09/2025
Our scientific evaluation of and opinions on the EPI-321 publicly available preclinical data 06/09/2025
Prequel for the Epicrispr Bio data and clinical trial discussion 06/09/2025
The nuts and bolts of gene therapy for FSHD (Part 2 of 2) 17/08/2025
The nuts and bolts of gene therapy for FSHD (Part 1 of 2) 15/08/2025
Part 2 of our discussion with our teen FSHD advocates 30/07/2025
Teens promoting their "Cure FSHD for All" initiative, podcast part 1 28/07/2025
MyFSHD is worldwide on FSHD Day 24/06/2025
Options for nutrition, supplements, and exercise for FSHDers with Tamara Gottlieb (Part 2) 25/04/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA